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Abstract
This paper reports results concerning the transfection of gliosarcoma cells 9L using an original cholesterol-based cationic liposome as
carrier. This cationic liposome was prepared from triethyl aminopropane carbamoyl cholesterol (TEAPC-Chol) and a helper lipid, dioleoyl
phosphatidyl ethanolamine (DOPE). The used concentration of liposome was not cytotoxic as revealed by the MTT test. TEAPC-Chol/DOPE
liposomes allowed the plasmids encoding reporter genes to enter the nucleus as observed both by electron microscopy and functionality tests
using fluorescence detection of green fluorescent protein (GFP) and luminometric measurements of luciferase activity. By changing the
cationic lipid/DNA molar charge ratio, optimal conditions were determined. Further, improvement of the transfection level has been obtained
by either precondensing plasmid DNA with poly-L-lysine or by adding polyethylene glycol (PEG) in the transfection medium. The optimal
conditions determined are different depending on whether the transfection is made with cells in culture or with tumors induced by
subcutaneous (s.c.) injection of cells in Nude mice. For in vivo assays, a simple method to overcome the interference of haemoglobin with the
chemiluminescence intensity of luciferase has been used. These results would be useful for gaining knowledge about the potential for the
cationic liposome TEAPC-Chol/DOPE to transfect brain tumors efficiently.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In light of the low efficacy of available treatments for
brain cancers, gene therapy appears to be a promising
solution (for review see Ref. [1]). Among brain cancer
models, one of the most studied is the gliosarcoma induced
by 9L cells [2,3].This model has been used in several
approaches of gene therapy, and attempts to treat gliosarco-
mas have been carried out, such as cytokine gene therapy
[4,5] or the use of antisense oligonucleotides [6]. For such
strategies, carriers are necessary for DNA transfer. Up to
now, gene carriers are mostly of viral type. Despite their
efficiency, viral vectors present serious drawbacks, because
immunogenicity and insertional mutations cannot be
excluded. As an alternative, nonviral gene carriers such as
cationic liposomes have been developed [7,8] and seem
attractive because they appear to be safe and are easy to
handle. Since the first experiments by Felgner et al. [9], it has
been shown that cationic lipids can efficiently transfect a
variety of cell lines in culture. Transfections in vivo were
successful and cationic lipid-mediated transfection has
shown promise for brain cancer gene therapy [10,11]. Pre-
vious studies have demonstrated interest in cholesterol-based
cationic liposomes for transfecting cancer cells [12,13].
Comparative experiments by Egilmez et al. [14] have shown
the superiority of cationic liposomes derived from cholesterol
over other cationic lipids in experiments in vivo.
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The original liposome developed for this work is based
on 3-h[N-(NV,NV,NV-triethyl aminopropane) carbamoyl] cho-
lesterol iodide (TEAPC-Chol). On one hand, cholesterol is
known for its stabilizing effect on liposomal membranes; on
the other hand, the ramified quaternary ammonium polar
head of TEAPC-Chol has been chosen assuming that such a
polar head will not be affected by the pH or charged
components in transfection media. TEAPC-Chol forms
stable liposomes when mixed with the helper lipid dioleoyl
phosphatidyl ethanolamine (DOPE).
After analyzing the characteristics of the association
between a DNA plasmid and TEAPC-Chol/DOPE lipo-
some, cytotoxicity has been evaluated. Using a green
fluorescent protein (GFP)-encoding plasmid, gene function-
ality was observed after liposome-mediated delivery of the
DNA in 9L cells. The cytolocalization of the carried plasmid
DNAwas explored by electron microscopy to understand its
behavior in the cellular environment. Using the luciferase
reporter gene system, we investigated the ability of this
cholesterol-based cationic liposome to transfect 9L cells in
vitro and tumors induced in vivo. We focused our attention
on studying conditions that improve the transfection effi-
ciency, especially the cationic lipid/DNA molar charge ratio
and the addition of polyethylene glycol (PEG) or poly-L-
lysine.
2. Materials and methods
2.1. Reagents
Cationic lipid TEAPC-Chol was synthesized and char-
acterized by Fourier Transform Infrared spectroscopy.
DOPE was purchased from Avanti Polar lipids (Alabaster,
AL). OPTIMEM, glutamax-containing DMEM medium,
Trypsin–EDTA, and PBS were obtained from Life Tech-
nologies (Paisley, UK). Reagents were furnished by Sigma-
Aldrich (Saint Louis, MI).
Plasmids encoding the h-galactosidase under the control
of cytomegalovirus (CMV) promoter (pCMV-h) and the
enhanced green fluorescent protein (pEGFP-N1) were pur-
chased from Clontech (Palo Alto, CA); pUT650 containing
luciferase reporter gene under the control of CMV promoter
was purchased from Cayla (Toulouse, France). DNA oligo-
nucleotide: 5V FITC–GAAAGAAGAAGCCGAAGAA-
GAAGGAGAA was used for cytometry and purchased
from Genosys (England).
2.2. Synthesis of TEAPC-Chol
3-h[N-(NV,NV,NV-triethyl aminopropane) carbamoyl] cho-
lesterol iodide or Chol-O-CO-NH-(CH2)3-N
+(C2H5)3I
 was
synthesized as follows: a solution of cholesteryl choloro-
formate (4.6 g; 102 mol) in 60 cm3 of anhydrous ether was
added dropwise into a solution of 3-diethylaminopropyl-
amine (2.65 g; 2102 mol) in 50 cm3 of ether at 0 jC.
After removal of hydrochloride by filtration, the solvent was
evaporated by using a rotary evaporator. The synthesis of
the quaternary ammonium iodide salt using the crude
residual carbamate in 50 cm3 of anhydrous tetrahydrofuran
was carried out by refluxing 12 h with an excess amount of
iodomethane (4102 mol). After removal of the solvent
and excess iodomethane, the recrystallization in absolute
methanol yielded 3.4 g (49%) of a straw-colored powder of
the pure cationic salt.
2.3. Liposome preparation
Cationic lipids TEAPC/Chol and amounts of DOPE at
various w/w ratios were dissolved and mixed in chloroform
and liposomes were prepared as described previously [13].
The preparations were controlled by negative staining
electron microscopy indicating that liposomes are unilamel-
lar. A mean size value of 108 nmF10 nm and a polydisper-
sity factor of 0.2 were obtained by quasi-elastic light
scattering (QLS) analysis.
2.4. Cell culture
Adherent tumoral cells 9L (rat gliosarcoma cells) were
obtained from ATCC and grown on plastic ware at 37 jC in
humid atmosphere containing 5% CO2 in air. The culture
medium DMEM containing glutamax was supplemented
with 10% fetal calf serum (FCS) and 50 U/ml penicillin/
streptomycin.
2.5. Formation of DNA/liposome complex and transfection
protocol
For the formation of DNA/liposome complex, DNA
(1Ag/Al) and liposomes TEAPC-Chol (1.5 mM) were sep-
arately diluted in equal volumes of sterile water and then
mixed to a final volume of 20 Al. The DNA/liposome
complexes formed instantaneously.
9L cells were seeded at 70% confluence in six-well plates
the day preceding the transfection. Best results are obtained
with 8105 9L cells per well. Just before transfection, the
culture medium was replaced with 1 ml OPTIMEM without
serum. Then DNA (3 nmol in nucleotide) and liposomes in
the tested Lipid/DNA ratios were added. After 6 h, OPTI-
MEM was removed and replaced with the serum-containing
culture medium, and the cells were incubated at 37 jC.
2.6. Gel retardation electrophoresis assay
DNA/TEAPC-Chol complexes were analyzed by electro-
phoresis in 1% agarose gel containing ethidium bromide
(0.5 Ag/ml) with a 0.04 M Tris–borate buffer, pH 7.4 at 60
V for 90 min. DNAwas visualized by UV illumination. Five
microliters of each complex was used. Wells with 12.5%
serum were supplemented to a final volume of 8 Al with 1 Al
of FCS.
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2.7. Cytotoxicity assay
Cytotoxicity was evaluated using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide reagent [MTT test].
Cells were seeded in 96-well plates at 5103 cells per well.
After 24 h of incubation, an increasing amount of TEAPC-
Chol/DOPE was added to triplicate wells. After 6 h, the
medium was removed and replaced with a serum-containing
medium. After 48 h, MTT (1 mg/ml) was added (100 Al/
well) to the cells and formazan crystals were allowed to
form during 3 h and further dissolved in dimethyl sulfoxide
(DMSO) (Sigma). Absorbance was measured at 570 nm on
a microplate reader (Bio-Rad), and the percentage of viable
cells was estimated by referring to the absorbance of
untreated cells.
2.8. GFP observation
The day before transfection, 9L cells (5104 per well)
were seeded onto a four-well permanox slide Lab-Tek
(Nunc, Napperville, IL). pEGFP-N1 (0.5 Ag) complexed
with TEAPC-Chol at optimal charge ratio was added to the
cells following the transfection protocol described above.
After 48 h of incubation, the media was removed and cells
were rinsed twice with PBS followed by a fixation step with
4% paraformaldehyde (PFA) in PBS. Fluorescence expres-
sion was observed with a Zeiss Axiophot fluorescence
microscope. Untransfected cells or cells with the plasmid
alone were used as controls.
2.9. Observation of labeled plasmids by immuno-gold
electron microscopy
For the preparation of digoxigenin-labeled plasmids, 0.4
Al of reactive digoxigenin (DIG-Chem-Link from Roche
Diagnostics, Meylan, France) was added in a sterile vial to 2
Ag of pCMV-h plasmid in a final volume of 20 Al. After
incubation for 30 min at 50 jC in a waterbath, the reaction
was stopped by adding 5 ml of the stop solution and stored
at 20 jC before transfection.
Cells dissociated from the wells of plate were fixed at 4
jC for 20 min in 1% PFA and 0.1% glutaraldehyde in 0.1 M
phosphate buffer pH 7.4 (PB). After washings, the cells
were treated for 10 min with 0.05% NaBH4 and 0.1%
glycine in PB, both to block the free aldehyde groups and
to permeabilize the cells. The cells were then rinsed in PB
and pre-incubated in 0.2% acetylated BSA (BSA-C) in PB
for 30 min. They were then incubated for 2 h at room
temperature with diluted ultra-small gold-labeled anti-
digoxigenin antibody Fab fragments (Aurion, Wageningen,
The Netherlands) in 0.2% BSA-C in PB. The cells were
rinsed in 0.2% BSA-C in PB, then in PB and refixed in
2.5% glutaraldehyde for 10 min. After washing in PB, the
samples were post-fixed with 0.5% OsO4 in PB for 20 min,
washed in deionized water and treated with the silver
enhancement reagent (Aurion). After washings in distilled
water, samples were stained in 0.5% uranyl acetate in 50%
ethanol, dehydrated in a graded series of alcohols, embed-
ded in Epon resin, sectioned, and examined with a Philips
EM300 transmission electron microscope operating at 60
kV.
2.10. Transfection level measurement
After the desired time of incubation, cells were twice
washed with PBS and lysed with the lysis solution furnished
in the chemiluminescence measurement Tropix kit (Applied
Biosystems, Bedford, MA). The level of the transfection
was estimated by measuring the quantity of expressed
luciferase following the procedure of the supplier. Lumino-
metric measurement was made using a BCL luminometer
operating at integration mode for 10 s. The calibration was
made by comparing with the luminescence of a luciferase
solution (Sigma) of known concentration. Protein was
titrated by using the Bio-Rad DC Protein assay kit (Her-
cules, CA) in order to normalize the results. The background
level was measured and subtracted. Each transfection
experiment was done in triplicate, and the mean is expressed
in relative light units (R.L.U) per milligram of total pro-
teinFstandard deviation or in relative transfection level,
expressed in percentage terms.
2.11. Flow cytometry
9L cells were seeded onto 24-well plates (105 cells/well).
The following day, 1 Ag of pEGP-N1 or 28 mer oligonu-
cleotide complexed to TEAPC-Chol/DOPE (1:1) at a charge
ratio of 2 was incubated with cells following the transfection
protocol. Commercial lipids associated with 1 Ag of pEGP-
N1 were used following the supplier protocol. After 24 h,
adherent cells were trypsinized and washed twice with PBS.
After resuspension in 1 ml of PBS, propidium iodide (PI)
(Sigma) was added to evaluate the proportions of living
cells and exclude dead ones. The cells were incubated with
PI in the dark at room temperature for 15 min before flow
cytometric analysis. For each sample 20,000 cells were
analysed using an Epics XL flow cytometer (Beckman
Coulter, Miami, FL) equipped with argon ion laser tuned
at 488-nm wavelength used for excitation. The emission
filters used were 530F30 nm band pass for green fluores-
cence of EGFP, and 620 nm long pass for red fluorescence
of PI. Data analysis was performed with System II software
(Beckman Coulter). The software permitted to obtain the
representation of the number of viable cells (selected by red
fluorescence of PI) as a function of fluorescence intensity of
EGFP or fluorescein (detected by green fluorescence).
2.12. Transfection level enhancement by poly-L-lysine and
PEG
Poly-L-lysine hydrobromide (MW: 19500) was obtained
from Sigma and diluted in water before use. Starting from a
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stock solution of 50 Al containing 0.975 mg of poly-L-
lysine, four aliquots of 5 Al containing, respectively, 19.5,
3.9, 0.78, and 0.15 Ag were prepared. Before complexation
with TEAPC-Chol, 1 Al of each aliquot was added to 1 Ag of
plasmid DNA. Concentrations of polylysine were chosen
assuming that 1 Ag of polylysine corresponds to 4.7 nmol of
positive charge.
PEG, MW: 8000, was obtained from Sigma and diluted
at 50% wt/v in sterile water. Just before transfection, various
amounts of PEG 50% were added to the transfection
medium to give desired percentages. Transfection was done
as described above.
2.13. Tumor transfection
Five-week-old nude (NMRI) mice were purchased from
Harlan (Belgium) and housed in microisolator cages. 9L
cells were trypsinized and collected during exponential
growth, washed twice in serum-free DMEM, and resus-
pended in PBS. Three subcutaneous (s.c.) tumors were
established by injecting 2106 cells in 100-Al PBS into
the flanks and the abdomen of nude mice and grown to 0.5–
1 cm in size. For intra-tumoral injections, animals were
anesthetized using Avertine, 500 Al/mice. In a final volume
of 100 Al, 20 Ag of pUT650 plasmid (1 Ag/Al) was
complexed with TEAPC-Chol/DOPE (3 mM) for 15 min
at the indicated charge ratio and injected. After 48 h, tumors
were removed and frozen for analysis. Each tumor was
measured, weighed, crushed, and homogenized in 200 Al of
lysis solution supplemented with 1 mM DTT, 0.2 mM
phenylmethylsulfonyl fluoride (PMSF), and 5 Ag/ml leu-
peptin. Centrifugation at 18,000g was used to eliminate
aggregates. Supernatants were collected, and the luciferase
activity was measured using the chemiluminescence assay
Tropix kit.
For these assays, because of the presence of blood in the
tumor lysates, the intensity of emitted light at 562 nm by
luciferase was underestimated due to the absorption by
haemoglobin presenting two peaks at 540 and 570 nm as
reported by Colin et al. [15]. To overcome this problem, we
used a simple two-step method to correct the measurements
of the luciferase intensity [16]. This protocol allowed to
avoid perfusion of tumors which was not easy to accom-
plish.
3. Results
3.1. Efficiency of complex formation
Seven different cationic lipid/DNA charge ratios were
analyzed by gel retardation in the absence of serum. A
typical result obtained by electrophoresis is shown in Fig.
1A. In this example, movement of an increasing fraction of
the plasmid in the gel is retarded as the amount of TEAPC-
Chol/DOPE is increased, demonstrating that the association
between negatively charged plasmid DNA and the cationic
lipid TEAPC-Chol/DOPE is based on electrostatic interac-
tions of charges of the two components. As no running band
of DNA is observed for ratios from 1.5, complete complex-
ation is achieved at a charge ratio of between 1.3 and 1.5.
One important parameter for any synthetic vector is the
ability to carry nucleic acids efficiently in the presence of
serum, especially for in vivo transfection. To obtain infor-
mation about the effect of serum on the stability and the
association of lipid with DNA in the complex, gel retarda-
tion assay has been repeated in the presence of serum (Fig.
1B). With 12.5% serum, the complete complexation
requires a greater amount of TEAPC-Chol/DOPE, as the
complexation is not achieved at the charge ratio of 2 but
rather between 2 and 4. This behavior suggested a competi-
tion between charged serum components and the DNA in
the binding to TEAPC-Chol/DOPE liposomes. Thus, an
excess of lipid may entrap serum proteins that interfere with
cationic lipid/DNA association.
In any case, the yield of the formation of DNA/TEAPC-
Chol/DOPE complex can reach 100% when the molar
charge ratio is appropriately chosen, even in the presence
of serum.
3.2. Evaluation of cytotoxicity
To know the consequences of adding lipidic molecules
on 9L cells, cytotoxicity of TEAPC-Chol/DOPE liposomes
was evaluated by MTT assay. Three formulations of DOPE/
TEAPC-Chol/liposome with ratios (wt/wt) of 0.5:1, 1:1, and
2:1 have been tested (Fig. 2). For this assay, liposomes at
ratios of 2:1 and 1:1 present the same IC50 of 52 AM;
however, the best cell viability at low concentrations of
liposomes are obtained with formulation of DOPE/TEAPC-
Chol at the ratio of 2:1. Before 20 AM any formulation gives
Fig. 1. Gel retardation assay of DNA/liposome complexation. (A) In
medium without serum. Lane 1: molecular weight marker (lambda HindIII);
lane 2: plasmid DNA alone; lanes 3–9: plasmid DNA complexed with
TEAPC-Chol/DOPE at molar charge ratio X=0.5 (lane 3), X=1 (lane 4), 1.3
(lane 5), X=1.5 (lane 6), X=1.7 (lane 7), X=2 (lane 8), and X=4 (lane 9). (B)
In medium containing serum. Lane 1: molecular weight marker (lambda
HindIII); lane 2: plasmid alone; lane 3: FCS (13%); lanes 4–7: plasmid
complexed with TEAPC-Chol/DOPE in the presence of FCS (13%) at
charge ratio X=0.5 (lane 4), X=1 (lane 5), X=2 (lane 6), and X=4 (lane7).
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a significant cytotoxicity (less than 50% viable cells). This
critical concentration is above threefold the concentration
used for in vitro experiments (6 AM). This demonstrates that
TEAPC-Chol/DOPE liposomes have a low cellular toxicity
and are suitable for transfection experiments on 9L cells.
Moreover, a small positive effect on cell growth has been
observed for TEAPC-Chol/DOPE (2:1) and (1:1) at the
lowest values corresponding to the range of concentrations
used for further in vitro experiments.
3.3. Expression of GFP
Using a plasmid encoding the GFP, we checked the
functionality of the GFP plasmid delivered by TEAPC-
Chol/DOPE liposome inside the 9L cells. Observations of
the cells 48 h after transfection clearly showed that vecto-
rization with TEAPC-Chol/liposome preserved the function-
ality of the plasmid, whose expression is shown in typical
cell fields (Fig. 3B). Controls with untransfected cells or
cells with the plasmid alone did not present any fluores-
cence (Fig. 3A).
3.4. Localization of the plasmid DNA after transfection
The cellular pathway of plasmid DNA carried by
TEAPC-Chol/DOPE liposomes was investigated by trans-
mission electron microscopy (TEM) using immuno-gold
labeling to distinguish the exogenous plasmid DNA from
the cellular DNA. The plasmid labeled with digoxigenin is
revealed by a gold-labeled antibody against digoxigenin. An
enhancement of the gold particle sizes was performed with
silver reagent. Finally, DNA can be observed among the
cellular DNA as dense black spots. Results of TEM obser-
vations of 9L cells after transfection are shown in Fig. 4.
Many gold particles are present inside the cell, and
clusters of plasmids can be found in the nucleus. All of
the controls with untransfected cells, treated with the silver
reagent alone or treated with antibody alone plus silver
reagent, did not show any black spots. The same was
observed when cells incubated with plasmids alone were
treated following the protocol described. These results
indicate that plasmids carried by TEAPC-Chol/DOPE lip-
osomes penetrated inside the nucleus.
3.5. In vitro transfection level
The ability of TEAPC-Chol/DOPE complexed with
DNA to transfect 9L cells in vitro was examined using
pUT650, a plasmid containing the luciferase reporter gene
under the control of the cytomegalovirus promoter. To
Fig. 2. Viability of 9L cells in the presence of cationic liposomes with three
different formulations of TEAPC-Chol and DOPE, evaluated by MTT assay
and expressed by the percentage referred to untransfected cells. Close
circles: TEAPC-Chol/DOPE at ratio (wt/wt) 2:1. Close squares: TEAPC-
Chol/DOPE at ratio 1:1. Open triangle: TEAPC-Chol/DOPE at ratio 1:2.
Each point is an average of three experimentsFstandard error.
Fig. 3. Expression of gene encoding for GFP transferred into 9L cells by
cationic liposomes. The pictures were obtained 48 h after transfection. (A)
Cells with plasmid pEGFP-N1 alone observed in epifluorescence. (B) Cells
transfected with plasmid pEGFP-N1 carried by TEAPC-Chol/DOPE (1:1)
observed in epifluorescence. (C) Same field observed by phase contrast.
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determine the optimal charge ratio of the complex for an
efficient transfection, seven cationic lipid-to-DNA molar
charge ratios have been tested. Results for TEAPC-Chol/
DOPE liposome (1:1) (w/w) are shown in Fig. 5. The
control presented a very low luciferase activity of the cells
transfected with the DNA alone, while the transfection level
varied with the charge ratio of the lipid/DNA complexes
added to the cells. Increasing the ratio from 0.5 to 2 resulted
in more than 18-fold increase in luciferase activity. The
three higher ratios show a significant decrease in efficiency
as a function of the molar charge ratio, indicating that the
best ratio is 2 for maximum transfection efficiency. These
results are consistent with the previous observation in gel
retardation assay regarding the fact that the charge ratio
should be higher than 1.3 for optimum complex formation.
The same experiments have been repeated with two other
formulations of liposome TEAPC-Chol/DOPE (1:0.5 and
1:2) (data not shown). The better transfection level has been
obtained for a molar charge ratio lip+/DNA equal to 2 for
TEAPC-Chol/DOPE (1:0.5) or 4 for TEAPC-Chol/DOPE
(1:2). However, the maximum transfection efficiency has
been obtained with TEAPC-Chol/DOPE (1:1) used at the
lipid/DNA charge ratio of 2; thus, this ratio and formulation
of the liposome have been used for further experiments
connected with this work.
To have more information about the efficiency of
TEAPC-Chol to transfect 9L cells, we used flow cytometry
to determine precisely the percentage of cells positive for
fluorescence of expressed GFP or for an FITC-labeled
oligonucleotide. In complement to luminometry measure-
ments made with a pool of cells, flow cytometry provided
useful individual data for each cell. Transfections of 9L cells
with three currently used monocationic lipids have been
performed to compare the efficiency between TEAPC-Chol
and these reagents (Table 1). The data illustrated the
advantage to use TEAPC-Chol/DOPE liposomes to carry
the plasmid DNA inside 9L cells in comparison to three
currently used monocationic lipids.
The behavior of TEAPC-Chol/DOPE in the presence of
serum has been investigated in transfecting 9L cells in
media containing increasing amounts of serum. As for
previous experiments, five different lipid to DNA charge
ratios have been used (Fig. 6). A maximum value of trans-
fection level was observed for each concentration of serum
Fig. 4. Pathway in 9L cells at 24 h after transfection of plasmids pCMV-h
vectorized by cationic liposomes TEAPC-Chol/DOPE (1:1) observed by
TEM. Plasmids, indicated by arrows, were labeled with digoxigenin,
detected by antibodies conjugated with gold particles enhanced by silver
reagent. (A) Whole cell observed at magnification 6800. (B) The same
field, focused on the nucleus at magnification 42000. (C) Focused view of
another nucleus at magnification 27,000. Bars represent 2 Am for (1A)
and 1 Am for (B) and (C).
Fig. 5. Transfection level of 9L cells by plasmid pUT650 delivered by
cationic liposomes TEAPC-Chol/DOPE (1:1), evaluated by luciferase
activity as a function of the cationic lipid/DNA molar charge ratio. Cells:
108/well; plasmid: 1 Ag; cationic lipid in the range 1.5–12 nmol; transfection
medium for the first 6 h: OPTIMEM without serum. After 6 h OPTIMEM
was replaced with the serum-containing culture medium DMEM. The
activity was expressed in RLU/mg protein per 10 s. Nonvectorized DNA is
used as control.
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used. This peak was shifted toward higher charge ratios
when transfection was carried out in media containing
increasing amounts of serum. Despite a decrease of the
transfection efficiency as a function of the serum concen-
tration, the transfection efficiency falls more than twofold
only for media containing 50% of serum. Consequently,
increasing the lipid/DNA charge ratio can improve the
transfection efficiency in the presence of increasing concen-
trations of serum.
3.6. Enhancement of transfection efficiency by addition of
PEG and poly-L-lysine
To increase the entry of TEAPC-Chol/DOPE/DNA com-
plex inside 9L cells in the presence of serum, we inves-
tigated the influence of PEG on the transfection level (Fig.
7). In the transfection media supplemented with 10% serum,
five different concentrations of PEG have been added. In
comparison with the control, results show a clear improve-
ment of the transfection level with all tested PEG concen-
trations in a concentration-dependent manner. A peak was
Fig. 6. Transfection level of 9L cells by plasmid pUT650 delivered by
cationic liposomes TEAPC-Chol/DOPE (1:1), evaluated by luciferase
activity as a function of the molar charge ratio in presence of increasing
concentrations of FCS. Cells: 108/well; plasmid: 3 nmol. Cationic lipid in
the range 1.5–12 nmol. Transfection medium for the first 6 h: OPTIMEM
without serum, white bars; OPTIMEM with 10% FCS, light grey bars;
OPTIMEM with 25% FCS, dark grey bars; OPTIMEM with 50% FCS,
black bars. After 6-h transfection, media was replaced with the serum-
containing culture medium DMEM. The activity was expressed by the
percentage of relative transfection level referred to the maximum
transfection level obtained without serum. Nonvectorized DNA is used as
control.
Fig. 7. Transfection level of 9L cells by plasmid pUT650 delivered by
cationic liposomes TEAPC-Chol/DOPE (1:1), evaluated by luciferase
activity as a function of increasing concentrations of PEG 8000 expressed
as percentage (wt/v) added to the media containing 10% FCS before
transfection. The plasmid DNA vectorized without PEG in the media is
used for control (100% relative activity).
Fig. 8. Transfection level of 9L cells by plasmid pUT650 delivered by
cationic liposomes TEAPC-Chol/DOPE (1:1), evaluated by relative
luciferase activity as a function of the poly-L-lysine amount added to 1-
Ag plasmid DNA assuming that 0.65 Ag of polylysine corresponds to 3.13
nmol of positive charge. Nonvectorized DNA is used for control.
Table 1
Comparison of transfection levels in 9L cells by TEAPC-Chol/DOPE and
three currently used monocationic liposomes
DNA Liposome Transfected cells (%)
pEGFP 0.30F0.08
+ Lipofectin 8.06F0.40
+ DC-Chol/DOPE 4.90F0.74
+ DMRIE-C 3.28F0.18
+ TEAPC-Chol/DOPE 12.53F0.60
Oligonucleotide 0.54F0.10
+ TEAPC-Chol/DOPE 57.3F4.7
Percentage of transfected 9L cells positive for the fluorescence of GFP or
FITC-labeled oligonucleotide vectorized by cationic liposomes TEAPC-
Chol/DOPE and lipofectin, DMRIE-C (Life Technologies). DC-Chol was
synthetized as indicated by Gao and Huang [18]. Cells: 105/well; plasmid
pEGFP-N1 and oligonucleotide: 1 Ag; cationic lipid: 6 nmol for TEAPC-
Chol/DOPE and DC-Chol/DOPE; otherwise as indicated by the suppliers;
incubation time, 24 h; other conditions, as described in text. Each point is
an average of three experimentsFstandard error.
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obtained with 4% PEG where an increase of about 10-fold
of the transfection level was observed.
The ability of TEAPC-Chol/DOPE to carry DNA into 9L
cells was enhanced by mixing plasmid DNA with poly-L-
lysine before complexation with TEAPC-Chol/DOPE and
cell transfection. Four different quantities of poly-L-lysine
have been used, each one furnishing various amounts of
positive charges interacting with the negative charge of the
plasmid DNA. In comparison with the control, results as
indicated by Fig. 8 showed an enhancement of the trans-
fection efficiency when 0.15 Ag of poly-L-lysine was added
to 1 Ag of DNA. Distribution of the results indicated a
concentration dependence of the enhancement, suggesting a
process implying accurate electric charge interactions.
3.7. In vivo gene transfer
To determine transfection efficiency in vivo, we induced
gliosarcoma tumors in nude mice by s.c. injection of 9L
cells. For those experiments, the plasmid DNA complexed
with TEAPC-Chol/DOPE (1:1) was directly injected in the
tumors. With indications from in vitro transfections, the
influence of the lipid/DNA charge ratio was tested for in
vivo experiments. With the total complex volume limited to
100 Al for the chosen DNA dose (20 Ag), precipitation
occurred when plasmid was associated with cationic lip-
osomes at high lipid/DNA charge ratios (X=4, 6, or 8).
Previous experiments with various batches of plasmid
and cationic liposomes at different concentrations demon-
strated that complex precipitation is a recurrent effect for
critical concentrations of the components (data not shown).
Despite those restrictions, we investigated the transfection
efficiency in vivo with three different lipid/DNA molar
charge ratios: 0.5, 1, and 2 (Fig. 9). Controls with PBS
solution indicated undetectable luciferase activity while the
unvectorized plasmid gave a nonnegligible luciferase activ-
ity. Nevertheless, the plasmid complexed with TEAPC-
Chol/DOPE at a charge ratio of 1 showed a significant
improvement of more than sixfold in comparison to the
naked plasmid. Ratios of 0.5 and 2 gave an identical or
inferior result, demonstrating that the charge ratio is a
critical parameter for efficient in vivo transfections. With a
less important dose of DNA (15 Ag) and a final complex-
ation volume of 150 Al, the same results have been obtained
(data not shown).
4. Discussion
The research of carriers is still a challenge for an efficient
transfer of foreign genetic materials into cancer cells. While
viral vectors present safety problems, nonviral vectors are a
promising alternative. However, many features of cationic
lipidic vectors have to be improved.
For DNA transfer into cells, several important conditions
must be fulfilled. The efficiency of the carrier to transport
DNA must be high. The DNA has to be protected against
enzymes in the extracellular medium. The complex DNA/
carrier must be internalized into the cell and the function-
ality of DNA has to be preserved for the expression of the
gene in the cell. Finally, the carrier must not be cytotoxic. In
the present work, liposomes formulated from an original
cationic lipid, TEAPC-Chol, in association with DOPE,
were used as the DNA carrier into a brain cancer model.
The results have shown that TEAPC-Chol/DOPE yields
a 100% association with a plasmid DNA at a molar charge
higher than 1.3. TEAPC-Chol/DOPE also exhibits a very
low cytotoxicity as revealed by the MTT assays. Local-
ization using TEM shows that plasmids can efficiently
penetrate into the nucleus when they are delivered by
TEAPC-Chol/DOPE. This process is a key step necessary
for gene expression and successful transfection. Moreover,
results using GFP or luciferase show that the vectorized
plasmids are fully functional.
An important result to emphasize is that the cationic
lipid/DNA molar charge ratio is a key point for transfection.
If the liposome bilayer structure is conserved, the neutral
charge ratio lip+/PO2
 should be 2 because only half the
number of lipid molecules are in the outer side of liposomes
interacting with DNA. On the contrary, if the liposome
structure is destroyed, all the cationic lipid molecules would
be associated with DNA and the neutral charge ratio would
be 1. In the light of this, a molar charge ratio in the range of
1 to 2 probably leads to the formation of a heterogeneous
distribution of complexes. This heterogeneity was remarked
in the studies of Cao et al. [13] and Zabner et al. [17]. The
various molar charge ratios used in this work showed
variable transfection levels in cells, indicating a correlation
between the structure of the complexes and the transfection
Fig. 9. Transfection level of in vivo 9L tumors by injection of plasmid
pUT650 vectorized by cationic liposomes TEAPC-Chol/DOPE (1:1) and
evaluated by luciferase activity as a function of cationic lipid /DNA molar
charge ratios. Phosphate buffer saline and non-vectorized pUT650 DNA
(20 Ag) are used as controls. Error bars correspond to confidence interval at
5% of four to six tumors. *: Statistical significance by Mann–Whitney U-
test with P=0.05.
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level. A similar behavior was observed with liposomes
prepared with DC-Chol, a cationic lipid close to TEAPC-
Chol [18]. A small excess of positive charges is probably
necessary for liposomes/DNA complexes to bind to the
cellular membranes, but this is not the only factor involved
in the cellular transfection. For transfection of CaSki cells
with oligonucleotides, Lappalanaien et al. [19] found that
oligonucleotide/liposome complexes were rapidly and effec-
tively taken up during endocytosis and transported into the
perinuclear area; however, the charge of the complexes
affects only the intracellular distribution of oligonucleotides.
These results indicate that the value of the optimum charge
ratio for an efficient transfection depends on the nature of
the lipidic vector, the carried DNA, and the cell line. Thus,
optimization is a necessary step for an efficient delivery. It is
worth noting that at the optimal charge ratio, comparison
experiment showed the advantage of using TEAPC-Chol/
DOPE over other formulations. Otherwise, the uptake of the
DNA does not correlate with the gene expression as
demonstrated by Ruponen et al. [20], and the values
observed for GFP expression could reflect this situation.
The use of a FITC-labeled oligonucleotide indicated the
ability of TEAPC-Chol to deliver DNA inside 9L cells with
57% of positive cells.
Transfection experiments carried out in the presence of
increasing amounts of serum showed a shift toward higher
values of the molar charge ratio giving the best transfection
level. The lipid bilayer of the liposome is a preferential
target of serum proteins as shown by Li et al. [21]. Highly
negatively charged molecules in the serum interacting with
cationic lipidic vectors lead to DNA release and degradation
[22]. The excess of charged liposomes in transfection
experiments in the presence of high serum concentration
could be a key point for explaining the better observed
results. Thus, a great amount of positively charged lipidic
molecules may protect DNA from release and degradation
due to competition by negative serum components. The gel
retardation assay results are relevant with this hypothesis.
McLean et al. [23] have demonstrated in an in vivo study a
serum-induced aggregation of DOTIM-cholesterol lipo-
somes vectors. As these aggregates exhibit a larger size
than free complexes, the penetration into tissues by the
endocytosis way, in particular into endothelial cells, would
be easier, resulting in a better transfection levels with high
serum concentration. On this assumption, in the presence of
serum, an excess of liposome in the complex may enhance
the aggregation of the vectors and lead to improve trans-
fection. Nevertheless, the constraints that the lipidic vector
undergoes in the conditions of an intravenous injection or in
a simple cell transfection in vitro are quite different and
remain to be explored.
Another point to be discussed is the role of the liposome
formulation of cationic lipid TEAPC-Chol and the helper
lipid DOPE. On one hand, DOPE is necessary for the
formation of the bilayer structure, but is also endosomolytic
[24]. On the other hand, cholesterol brings rigidity to the
liposome structure, but is also known to modulate the
hydrocarbon chain fluidity of the lipidic molecules of the
cell membrane [25]. Thus, TEAPC-Chol associated with
DOPE at ratio 1:1 may depict a good balance between rapid
self-aggregation and a persistent resistance to serum.
Because rare informations have been published about inter-
actions between cationic lipids and serum proteins, further
investigations are necessary to identify which proteins are
involved and which structures and parts of the cationic lipid
molecule are important. Despite the hypothesis explaining
the better transfection levels with a higher molar charge
ratio, serum interactions still induce a global decrease of
transfection efficiency. However, increasing the molar
charge ratio is a way to minimize the influence of serum
over TEAPC-Chol/DOPE/DNA complexes.
Regarding in vitro results, transfection levels of 9L cells
can be enhanced by adding PEG 8000 in the transfection
media or using poly-L-lysine associated with DNA. In both
kinds of experiments, transfection levels have been
improved in a dose-dependent manner.
The entry in the cytoplasm is the first important step for
liposome-mediated transfection. Yang et al. [26] showed
that a low concentration of PEG could induce liposome
aggregation, increasing the association between cell mem-
branes and lipid/DNA complexes. This better association
results in better penetration of the complexes, as demon-
strated by Ross and Hui [27]. Our observations on 9L cells
agreed to the conclusions of Yang et al. [26]. Finally, PEG
seems to be an important factor to enhance the cytoplasmic
penetration.
The nuclear transport of the DNA following the cyto-
plasmic penetration is also another limiting step. Recently,
the role of poly-L-lysine in the nuclear transport process has
been investigated [28]. Assuming that poly-L-lysine can
mimic a nuclear localization signal (NLS), we attempted
to increase the ability of DNA to enter the nucleus by
adding poly-L-lysine to the plasmid. Thus, it may be that the
observed improvement of the transfection is due to a better
nuclear importation of the DNA contributed by polylysine.
Zauner et al. [28] proposed such a role for polylysine using
primary human fibroblasts. Apart from polylysine-mediated
nuclear transport, alternative explanations may also be
suggested. Protection of the DNA from a cytoplasmic
degradation could be a possible explanation for improve-
ment by poly-L-lysine. The ability of the poly-L-lysine to
condense DNA may also enhance the transfection level by
facilitating the DNA penetration in cells.
Another important result concerns in vivo experiments.
Regarding transfection of the tumors induced by 9L cells,
results are not relevant to in vitro assays done with high
serum concentration. Surprisingly, the best result was
obtained with the molar charge ratio of TEAPC-Chol/DOPE
to DNA complex of 1 and not with the ratio of 2 or higher as
for the in vitro transfection in the presence of serum.
However, these observations must take into account the
precipitation of the complex occurring at high molar charge
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ratios. Clark et al. [29] have reported the same behavior
common to cationic lipids. Felgner [30] mentioned that
trying to mimic in vivo conditions by adjusting in vitro
assays leads to very unexpected results. The behavior of the
lipid/DNA complex in the intratumoral environment is
probably the key point in relation to a change of structure
and properties, which may affect the permeation of DNA.
As proposed by Clark et al. [29], complexation of plasmid
DNAwith cationic lipid may improve DNA retention in the
tumor and thus its penetration in cells. However, an excess
of cationic lipid in the tumoral tissue could lead to a stronger
retention but at the same time appears unfavorable to DNA
expression as observed. One would think that the conditions
of an efficient in vivo transfection should be obtained by an
accurate balance between the antagonist effects due to Lip+/
DNA ratios. On the other hand, as in the case of muscle
where Schwartz et al. [31] have demonstrated that naked
DNA alone could penetrate efficiently into brain cells, a
nonnegligible luciferase activity was observed in 9L cells
transfected with the plasmid alone. However, free DNA is
not protected from degradation so that the level was not as
high as in the case of DNA associated with liposome.
For those experiments in vivo, it is also worth noting that
the interference of haemoglobin with the luciferase measure-
ment of tumor samples has been overcome by an original
approach [16]. The values of the luciferase activity are
reproducible and do not fluctuate with the uncontrolled
amounts of haemoglobin present in the analyzed samples,
regardless of the haemoglobin quantity.
In conclusion, results of this work demonstrated that
cationic liposomes prepared from TEAPC-Chol are promis-
ing vectors to carry plasmid DNA efficiently into gliosar-
coma 9L both in vitro and in vivo. Optimization of the
transfection levels can be achieved with an appropriate
choice of the lipid/DNA molar charge ratio in combination
with the use of poly-L-lysine or PEG.
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